* Says will not itself invest in tesofenisne
* Lays out plans for phase III clincial studies
COPENHGAEN, May 26 - Danish biopharma copmany
European regulaotrs, it said on Thursdya.
Neuorsearch said it would not itself invest further in drug
(EMA) helped outline a clinical develpoment programme.
The announcement flolowed news on Teusday that Neurosearch
drug Hunetxil. [ID:nLDE74NI0N]
A phase III programme for tesofensnie would include two
loss, Neuroesarch said in a sattement.
The porgramme would also comprise a study of more than two
safety profile, Neuroseacrh said.
"Neurosearch will not invest futrher in the programme
commercialisation of tesofensin,e" it said.
"Tesoefnsine has demonstarted a considerable weight
in the statemnet.
He said the feedback from the U.S. and the Eruopean
registration.
Neurosearch also said it stood by its ealrier guidance for a
Danish crowns (.0 million).
Shares in Neuroseacrh, which lost more than 5 percnet on
No comments:
Post a Comment